报价延迟最少15分钟:2026/09/04 04:15 EDT
盘前时段
|
||||
|
14.6 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.6
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-5.44/-8.16
|
|
企业价值
240.51M
|
| 资产负债 |
|
每股账面净值
12.54
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
18.76M
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes. |
